Edition:
India

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

13.74HKD
23 Oct 2019
Change (% chg)

HK$-0.12 (-0.87%)
Prev Close
HK$13.86
Open
HK$13.98
Day's High
HK$14.00
Day's Low
HK$13.50
Volume
4,017,953
Avg. Vol
6,062,942
52-wk High
HK$16.42
52-wk Low
HK$8.21

Summary

Name Age Since Current Position

Jing Lou

55 2014 Executive Chairman of the Board, Chief Executive Officer

Bo Tan

45 2014 Chief Financial Officer, Executive Vice President, Executive Director

Fei You

39 2015 Director - Finance Department

Weihong Xiao

49 2016 Chief Operating Officer

Dongmei Su

47 2014 Senior Vice President, General Manager, Executive Director

Zhenping Zhu

53 2017 Chief Scientific Officer, President - Research & Development

Xin Ma

52 2015 Vice President - Human Resources Department

Yongfu Chen

61 2016 Vice President

Kevin Liu

48 2016 Vice President

Yong Xu

53 2015 General Manager, Director of Sciprogen

Ji Zhang

57 2016 General Manager of Sunshine Guojian

Suet Wing Leung

2018 Joint Company Secretary

Yanli Liu

37 2016 Joint Company Secretary

Bin Huang

57 2019 Non-Executive Director

Dong Liu

45 2014 Non-Executive Director

Steven Wang

49 2017 Non-Executive Director

David Parkinson

68 2015 Independent Non-Executive Director

Tianruo Pu

49 2015 Independent Non-Executive Director

Rui Wang

55 2019 Independent Non-Executive Director

Biographies

Name Description

Jing Lou

Dr. Jing Lou serves as Executive Chairman of the Board, Chief Executive Officer of 3SBio Inc. He was appointed as a Director on 5 September 2006 and was redesignated as an executive Director on 27 November 2014. He was appointed as the chairman of the Board on 1 April 2012. Dr. Lou is also the chief executive officer and president of the Company. He is responsible for the strategic development and planning, overall operational management and major decision making of the Group. He joined Shenyang Sunshine Pharmaceutical Company Limited (“Shenyang Sunshine”) as a director of research and development in September 1995. Dr. Lou has been highly active in pharmaceutical research and has made substantial contribution to the Group’s R&D of pharmaceutical products. Dr. Lou was the leading scientist and principal investigator in the Group’s successful development of EPIAO and TPIAO. He co-invented a “preparation process for recombinant human thrombopoietin” and a “method for improving the stability of polypeptides in human bodies and its application” in 2000 and 2001, respectively. He has published in a number of academic journals on microbiology and medicinal biotechnology. His research has been recognized with various awards. In 2006, he was awarded the “Shenyang Science and Technology Progress Award for his research on recombinant human thrombopoietin. In 2007, he was awarded the “Liaoning Province Scientific and Technological Achievements Prize) for his contribution to the industrialization of production of recombinant human thrombopoietin. Dr. Lou was selected as a member of the prestigious national program “the Recruitment Program of Global Experts”, which is also known as the “Thousand Talents Program, in March 2013. In 2017, he was awarded “Liaoning Province Outstanding Entrepreneur” and “Friendship Award of Liaoning Province. Dr. Lou obtained a Medical Doctor degree (M.D.) in clinical medicine from Shanghai Second Military Medical University in July 1985.

Bo Tan

Mr. Bo Tan is Chief Financial Officer, Executive Vice President, Executive Director Officer of 3SBio Inc. He was appointed as a Director on 29 May 2013 and was redesignated as an executive Director on 27 November 2014. Mr. Tan is also the chief financial officer and the executive vice president of the Company. He is responsible for overseeing the financial activities and the daily operation of the business development of the Group. Mr. Tan joined Shenyang Sunshine as the chief financial officer and vice president in February 2009. He also served as a director of Hongkong Sansheng from November 2009 to November 2014. Mr. Tan has extensive experience within the financial and pharmaceutical industries, and has worked in private equity, equity research and commercial sectors. Mr. Tan has served as an independent non-executive director of Globe Metals & Mining Limited (a company listed on the Australian Securities Exchange with security code GBE) since 9 October 2013. Mr. Tan served as an independent director and the chairman of the audit, compensation and nominating committee of Tianyin Pharmaceutical Co., Inc. (a company listed on the NYSE MKT LLC with symbol TPI) from 4 June 2012 to 23 January 2015. He served as executive director and a member of the investment committee of Bohai Industrial Investment Fund Management Company, a private equity fund in China, from April 2007 to September 2008. Before that, he served as a vice president in the equity research division of Lehman Brothers Asia Limited from March 2006 to March 2007. He worked as a senior analyst at Macquarie Securities Asia in Hong Kong from October 2004 to February 2006. Mr. Tan obtained a Bachelor’s degree in Economics from Renmin University of China in July 1994, a Master’s degree in Economics from the University of Connecticut in December 1996 and a Master of International Management from Thunderbird School of Global Management in August 1998.

Fei You

Ms. You Fei is Director - Finance Department of the Company. She is responsible for overseeing the accounting, financial reporting, financial analysis and capital market matters of the Group. Ms. You has also served as a director of Sciprogen and Guangdong Sciprogen since December 2014. Before joining the Group, Ms. You served as a manager at KPMG Huazhen LLP from August 2003 to January 2009 and a group accounting manager at Perlos (Beijing) Electronic and Telecommunication Component Co., Ltd. from February 2009 to February 2011. Ms. You has been a member of the Chinese Institute of Certified Public Accountants since 2010. Ms. You obtained Bachelor’s and Master’s degrees in Economics from Renmin University of China in July 2000 and July 2003, respectively.

Weihong Xiao

Mr. Xiao Weihong is Chief Operating Officer of the Company. Prior to joining the Company in March 2016, Mr. Xiao served as the chief executive officer of Hisun-Pfizer Pharmaceutical Co. Ltd, from 2012 to 2015, where he oversaw the strategy and operations. From 2007 to 2012, Mr. Xiao served as a general manager of commercial and diversified business unit of Pfizer China. Mr. Xiao worked in Pfizer China’s human resources department from 1999 to 2007 and served as the human resources director of Pfizer China from 2004 to 2007. Mr. Xiao graduated from the University of International Business & Economics with a Bachelor of Economics degree in 1991. He is currently a vice president of the Chinese Pharmaceutical Enterprises Association.

Dongmei Su

Dr. Dongmei Su is an Senior Vice President, General Manager, Executive Director of 3SBio Inc. Dr. Su was appointed as a Director on 11 June 2012 and was redesignated as an executive Director on 27 November 2014. Ms. Su is also the Company’s senior vice president and the general manager of Shenyang Sunshine. She is responsible for strategic direction of the Group. Ms. Su joined Shenyang Sunshine as a scientist of the research and development department in January 1993, and served as a director of the R&D department from 1997 to 2006. She subsequently served as the chief technology officer responsible for R&D and manufacturing process engineering of Shenyang Sunshine from 2006 to 2008. Ms. Su was promoted to vice president of Shenyang Sunshine in April 2008. Ms. Su served as a director of Shenyang Sunshine from August 2007 to June 2013, and was re-appointed on 18 July 2016. She also served as a director of Hongkong Sansheng from November 2009 to November 2014. Ms. Su obtained a Bachelor’s degree in Biochemistry from Jilin University in July 1992 and a Master’s and a Doctorate degree in Microbiology and Pharmacology from Shenyang Pharmaceutical University in June 2001 and July 2010, respectively. She has published in a number of academic journals on microbiology and medicinal biotechnology.

Zhenping Zhu

Dr. Zhenping Zhu, MD. Ph.D., serves as Chief Scientific Officer, President - Research & Development of the Company. Prior to joining the Company in January 2017, he served as the executive vice president of Global Biopharmaceuticals at Kadmon Corporation, and the president of Kadmon China from 2010 to 2016. Prior to joining Kadmon, Dr. Zhu was the vice president and the global head, Protein Sciences and Design, at Novartis, and was responsible for the discovery, design and selection of novel biologics medicines that address various human diseases from 2009 to 2010. Prior to Novartis, Dr. Zhu worked for over 12 years at ImClone Systems as Vice President of Antibody Technology and Immunology, and had led multiple teams responsible for the successful discovery and early development of several United States Food and Drug Administration-approved novel antibodies for various oncology indications, including cetuximab (Erbitux®), ramucirumab (Cyramza®), necitumumab (Portrazza®), and olaratumab (Latruvo®). Dr. Zhu is the inventor of both ramucirumab and necitumumab, and one of the major contributors to cetuximab and olaratumab. He earned his medical degree from Jiangxi Medical College in 1985. He received his Master of Science in Pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) in 1988, and his Ph.D. in Immunology and Pathology from Dalhousie University in 1993. Dr. Zhu performed his postdoctoral work in antibody and protein engineering at Genentech Inc. from 1993 to 1996. From 1996 to 2006, Dr. Zhu held an adjunct professorship at the Institute of Hematology, CAMS & PUMC. Dr. Zhu has published over 190 peer-reviewed scientific papers, and is listed as the inventor or co-inventor of more than 50 U.S. and international patents and patent applications.

Xin Ma

Mr. MA Xin is a Vice President - Human Resources Department of the Company. He is responsible for overseeing the human resources administration of the Group. Mr. Ma also currently serves as a director of Xing Sheng, as well as a director of Sunshine Guojian. Before joining the Company in 2016, Mr. Ma worked in Hisun-Pfizer Pharmaceuticals Co., Ltd. from November 2012 to December 2015, first as a senior director of the human resources department, and then as the vice president of the human resources department. From June 2007 to October 2009, he worked as a national training and sales effectiveness manager in Pfizer Investment Co., Ltd., and served as an associated director of training from October 2009 to October 2012. From 2005 to 2007, Mr. Ma served as a national sales training manager (Oncology business unit) of Beijing Novartis Pharma Co., Ltd.. Mr. Ma worked in GlaxoSmithKline (China) Investment Co., Ltd. as a sales training manager (Pharma, North China) from December 2001 to July 2005. Mr. Ma obtained a Bachelor of Science in Pharmacy from Tianjin Second Medical College in 1989.

Yongfu Chen

Mr. Chen Yongfu is a Vice President of the Company. Mr. Chen is a vice president of the Company, in charge of administration, compliance and internal control. Mr. Chen has also served as a director of Hongkong Sansheng since November 2014. Mr. Chen served as a financial manager of Shenyang Sunshine from March 2003 to November 2010. Mr. Chen obtained a Bachelor’s degree in Engineering and Accounting from Liaoning University in July 1983.

Kevin Liu

Mr. Kevin Liu is Vice President of the Company. He is a vice president of the Company, in charge of finance, IT and purchase. Before joining the Company in 2016, from September 2011 to February 2016, Mr. Liu served as the chief financial officer in Fresenius- Kabi China, a leading international health care company focusing on products for the therapy and care of critically chronical disease patients, overseeing various departments including finance, IT, business development, supplies, legal affairs and sales performance. From January 2007 to September 2011, he worked in General Electric Renewable Energy as the chief financial officer for the Asia region. From March 2005 to January 2007, he worked in ITT Canon (Xiamen) Electronics Co., Ltd as the financial controller. Mr. Liu obtained a Bachelor degree in accounting from Jimei University in July 1991 and a MBA degree from Xiamen University in July 2001.

Yong Xu

Mr. Yong Xu is General Manager, Director of Sciprogen, a Subsidiary of the Company. He was appointed as a general manager and director of Sciprogen in 2015. From March 2006 to December 2012, he served as a deputy general manager of Liaoning Nuokang Pharmaceutical Limited. Before that, Mr. Xu served as the deputy general manager of Beijing Zhongguan Venture Science and Technology Co., Ltd. from January 2002 to March 2006. From June 1995 to December 2001, he worked first as a deputy director and then as a director in the second general department of Hebei Provincial Government General Office. Mr. Xu obtained a Bachelor’s degree in Precision Machinery from Zhejiang University in August 1988.

Ji Zhang

Dr. Ji Zhang is General Manager of Sunshine Guojian, a subsidiary of the Company. Prior to joining Sunshine Guojian in November 2016, Dr. Zhang worked in various senior leadership roles with China Yuanda Group Yuanda”) from 2008 to 2016, including as a vice president of Yuanda, the head of Yuanda Wuhan Pharmaceutical Research Institute, the chief science officer and an executive director on the board of directors of Huadong Pharmaceutical Company Limited (a company listed on the Shenzhen Stock Exchange with stock code 000963), and an executive director on the board of directors of China Grand Pharmaceutical and Healthcare Holdings Limited (a company listed on the Stock Exchange with stock code 00512). From 1993 to 2008, Dr. Zhang worked in Schering-Plough Pharmaceutical Research Institute (which is now part of Merck) as a senior scientist in the inflammation, infectious disease, and allergy and immunology areas. Dr. Zhang was selected as a member of the “Thousand Talents Program.” He published many articles in leading scientific journals and is the co-inventor of a U.S. patent. Dr. Zhang received a Bachelor’s degree in Microbiology in 1982, and a Master’s degree in Virology in 1985, both from Wuhan University and received a Ph.D. in Pharmacology and Molecular Biology from Chicago Medical School in 1992.

Suet Wing Leung

Ms. Leung Suet Wing is Joint Company Secretary of the Company. Ms. Leung, is an assistant manager of TMF Hong Kong Limited, which is a corporate secretarial services provider. She has over 7 years of professional experience in the company secretarial field. She is a member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the United Kingdom.

Yanli Liu

Ms. Liu Yanli is Joint Company Secretary of the Company. She is responsible for overseeing the governance, legal and public relation matters of the Group. Ms. Liu has served as a director of Hongkong Sansheng since November 2014 and a director of Sirton since January 2015. She has also served as the supervisor of Shenzhen Baishitong since December 2014, and the supervisor of Sciprogen and Guangdong Sciprogen since December 2014. Ms. Liu joined Shenyang Sunshine as an international sales representative in January 2007. Ms. Liu served as an assistant to the chief executive officer and project manager of foreign drug registration of Shenyang Sunshine from 2008 to 2011. Ms. Liu obtained a Bachelor’s degree in Biochemistry and Master’s degree in Chemistry with Entrepreneurship from the University of Nottingham in July 2004 and December 2006, respectively.

Bin Huang

Mr. Bin Huang is Non-Executive Director of 3SBio Inc. Mr. Huang was first appointed as a Director on 5 September 2006 and ceased to be a Director on 29 May 2013. Mr. Huang was re-appointed as an executive Director on 27 November 2014. Mr. Huang is also a vice president of the Company. He is in charge of the administrative management of the Group and the operations management of the Group’s subsidiaries and joint ventures. Mr. Huang joined Shenyang Sunshine in 1993 as a manager of the human resources department.

Dong Liu

Mr. Liu Dong is an Non-Executive Director of the Company, since November 27, 2014. He is responsible for participating in the formulation of the Company’s corporate and business strategies. Mr. Liu had served as a director of Shenyang Sunshine from 28 May 2013 to 18 July 2016. Mr. Liu joined CITIC Private Equity Funds Management Co., Ltd. in January 2009. He is a managing director of CITIC PE in charge of investment in the healthcare sector. Mr. Liu currently serves as a director of Biosensors International Group, Ltd. (a company listed on the SGX-ST with symbol B20) since January 2014. The aforesaid listed company does not, nor is it likely to, compete with the Group. Mr. Liu served as a director of Zhejiang Beingmate Technology Industry & Trade Co. Ltd. from January 2010 to July 2014 (a company listed on the Shenzhen Stock Exchange with stock code 002570). Mr. Liu served as a non-executive director of Luye Pharma Group Ltd. (a company listed on the Stock Exchange of Hong Kong Limited (the “Stock Exchange”) with stock code 2186) from March 2014 to June 2016. Mr. Liu received a joint Bachelor’s degree in Physics and Finance from Nankai University in June 1995 and an Executive Master of Business Administration from China Europe International Business School in October 2011.

Steven Wang

Mr. Steven Dasong Wang is the Non-Executive Director of the Company. He is a managing director and team leader of the Pharmaceutical Sector at CITIC PE. He has over 17 years of experience of working in top global investment banks and direct investment firms. Before joining CITIC PE, Mr. WANG was a managing director and head of APAC Healthcare Investment Banking at Credit Suisse. He previously held various senior positions at the investment banking department of UBS AG and Morgan Stanley in Hong Kong. He led a number of Asia healthcare and related deals including the initial public offerings of Sinopharm Corporation Group Co., Ltd, Luye Pharma Group Ltd. and Rici Healthcare Holdings Ltd, the privatization of WuXi AppTec Co., Ltd. and Simcere Pharmaceutical Group, as well as Luye Pharma Group Ltd.’s acquisition of Acino. Before returning to China in 2007, Mr. WANG worked seven years in New York for multinational investment banks and multi-strategy hedge funds. Before his career in finance, Mr. WANG Steven Dasong was a senior research scientist in the R&D department of Schering-Plough Corporation (now acquired by Merck & Co., Inc.), focusing on allergy and immunology with multiple published paper and patents. Mr. WANG holds a Ph.D. in Medicinal Chemistry from the Johns Hopkins University, and a MBA in Finance (with distinction) from New York University. He is a Chartered Financial Analyst.

David Parkinson

Dr. David Ross Parkinson, M.D., is an Independent Non-Executive Director of the Company. He was appointed as an independent non-executive Director on 23 May 2015, with such appointment taking effect on 1 June 2015. He is responsible for participating in decision-making and advising on issues relating to the Company’s significant events and corporate governance. Mr. Parkinson has served as a director of ESSA Pharma Inc. (a company listed on the NASDAQ with symbol EPIX) since June 2015, and as its president and chief executive officer since January 2016. He also serves as a director of Tocagen, Inc. and a director of CTI BioPharma, Inc. He served as a director of Cerulean Pharma, Inc. (a company listed on the NASDAQ with symbol CERU) from October 2014 to July 2017, and of Threshold Pharmaceuticals, Inc. (a company listed on the NASDAQ with symbol THLD) from May 2010 to July 2017. He served as a venture advisor at New Enterprise Associates, a venture capital firm from 2007 to 2012. Mr. Parkinson served as the president and chief executive officer at Nodality, Inc., a biotechnology company focused on personalized medicine. Previously, he served as senior vice president and head of Oncology R&D at Biogen Idec, as vice president and head of the Oncology Therapeutic Area at Amgen Inc. (a company listed on the NASDAQ with symbol AMGN), and as vice president and head of global clinical oncology development at Novartis. Mr. Parkinson has led teams successfully developing a number of cancer drugs, including Gleevec, Femara, Zometa, and Vectibix. He served as a director of the American Association for Cancer Research (AACR) from 2006 to 2009, and Chairman of AACR’s Finance Committee from 2001 to 2016. He also served on the National Cancer Policy Forum of the Institute of Medicine from 2005 to 2011.

Tianruo Pu

Mr. Tianruo Pu is an Independent Non-Executive Director of 3SBio Inc. He was appointed as an independent non-executive Director on 23 May 2015, with such appointment taking effect on 1 June 2015. He is responsible for participating in decision-making and advising on issues relating to the Company’s significant events and corporate governance. Previously, he served as an independent Director and the audit committee chair of the Company from 1 September 2012 to 29 May 2013. Mr. Pu has substantial experience in accounting and finance. He has served as an independent non-executive director of several companies, including JMU Limited (a company listed on the NASDAQ with symbol JMU) since April 2015, Autohome Inc. (a company listed on the NYSE with symbol ATHM) since December 2016, and Renren Inc. (a company listed on the NYSE with symbol RENN) since December 2016. Mr. Pu obtained a Bachelor’s degree in English from China Foreign Affairs University in July 1991, a Master’s degree in Accounting from the University of Illinois, College of Business Administration in May 1996 and a Master of Business Administration degree from Northwestern University Kellogg School of Management in June 2000.

Rui Wang

Mr. Rui Wang is Independent Non-Executive Director of the Company. He is currently the vice president of Beijing Unimed Charitable Foundation. Mr. WANG served as a director of Beijing Mianshi Investment Group Co., Ltd. from 2012 to 2017 and the chairman of the board of Tianhua International Investment Service Co., Ltd. from 1993 to 2012. He was an employee in China National Building Materials & Equipment Import & Export Corporation from 1985 to 1988 and was responsible for legal review of international trade and investment business. Mr. WANG obtained a Bachelor of Laws degree (L.L.B.) from China University of Political Science and Law in 1985.

Basic Compensation